Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digene licenses cervical cancer marker:

This article was originally published in Clinica

Executive Summary

Molecular diagnostics company Digene has obtained worldwide rights to a genetic marker linked to cervical cancer. The p53arg gene, which the Beltsville, Maryland-based company licensed from McGill University in Montreal, Canada and the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy, has been shown to predict cancers related to the human papillomavirus (HPV), of which cervical cancer is one. Digene's lead product is a DNA test for the HPV virus and is used as an adjunct to Pap smear testing in the US. A test for the p53arg gene could make HPV testing more effective for earlier cancer prognosis, said Digene.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT082779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel